Amid high decibel deliberations on Covid-19 pandemic, something similar to groundbreaking happened – involving Biosimilar drugs, in just a couple of months ago. On July 28, 2021, in the Eldorado of the pharma industry, the US-FDA approved the first ‘interchangeable’ biosimilar drug, … Continue reading
Tag Archives: Biologic
Spirit Behind Drug Patent Grant: Secondary Patents: Impact on Drug Access
For more effective treatment against existing diseases, besides combating new or a more complicated form of existing ailments with precision, drug innovation is absolutely necessary and on an ongoing basis. This makes innovative drugs so important for the population, globally. … Continue reading
Is India A Success Story With Biosimilar Drugs?
How Indian generic companies are expanding, if not shifting their business focus on biosimilar and complex generic drugs, may be a current trend of general discourse – but the initiative is not a current one. This journey commenced decades ago … Continue reading
A ‘Toxin’ Delaying Success of Biosimilar Drugs
The above comment, although sounds a bit harsh, was made recently by none other than Scott Gottlieb - the Food and Drug Administration Commissioner of the United States. He expressed his anguish while explaining the reasons for a delayed launch of several important … Continue reading
‘Rigged’ Payment System Limits Biosimilar Access
As often discussed, market entry of biosimilars, in general, brings a new hope not just for many patients, but also to biosimilar drug manufacturers – planning to get marketing approvals of these drugs in the United States, the El Dorado … Continue reading
Patent Expiry No Longer End of The Road
Who says that the phenomenal success of blockbuster drugs is mostly eaten away by ‘look-alikes’ of the same, immediately after respective patent expiry? It doesn’t seem to be so any longer, not anymore! Several examples will vindicate this emerging trend. … Continue reading
Improving Patient Access To Biosimilar Drugs: Two Key Barriers
Novel biologic medicines have unlocked a new frontier offering more effective treatment for a host of chronic and life-threatening diseases, such as varieties of cancer, rheumatoid arthritis and diabetes, to name just a few. However, these drugs being hugely expensive, … Continue reading
Is Criticizing Pharma Now Just A Fad?
Is criticizing pharma now just a fad of its stakeholders? Fathoming the right answer to this seemingly simple question may not be too easy, either, for some. The task could even be more onerous, especially when the global ‘researched based’ … Continue reading